Copyright
©2013 Baishideng Publishing Group Co.
World J Gastrointest Oncol. Jun 15, 2013; 5(6): 102-112
Published online Jun 15, 2013. doi: 10.4251/wjgo.v5.i6.102
Published online Jun 15, 2013. doi: 10.4251/wjgo.v5.i6.102
Complete metabolic response | Complete resolution of [18F]-FDG uptake within the tumor volume indistinguishable from surrounding normal tissue |
Partial metabolic response | Reduction of a minimum of 15%-25% in tumor [18F]-FDG SUV after one cycle of chemotherapy Reduction of a minimum of > 25% in tumor [18F]-FDG SUV after more than one treatment cycle |
Progressive metabolic disease | Increase in [18F]-FDG tumor SUV > 25% within the tumor region, visible increase in the extent of [18F]-FDG tumor uptake (> 20% in the longest dimension) Appearance of new [18F]-FDG uptake. |
Stable metabolic disease | Increase in tumor [18F]-FDG SUV < 25%, decrease of < 15%. No visible increase in extent of [18F]-FDG tumor uptake (< 20% in the longest dimension) |
- Citation: Rammohan A, Sathyanesan J, Rajendran K, Pitchaimuthu A, Perumal SK, Srinivasan U, Ramasamy R, Palaniappan R, Govindan M. A gist of gastrointestinal stromal tumors: A review. World J Gastrointest Oncol 2013; 5(6): 102-112
- URL: https://www.wjgnet.com/1948-5204/full/v5/i6/102.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v5.i6.102